These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23757292)

  • 1. Vaccines for low-income countries.
    MacLennan CA
    Semin Immunol; 2013 Apr; 25(2):114-23. PubMed ID: 23757292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa.
    Okoko BJ; Idoko OT; Adegbola RA
    Vaccine; 2009 Mar; 27(14):2023-9. PubMed ID: 19095025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we defeat meningococcal disease in low and middle income countries?
    Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
    Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of vaccines for prevention of bacterial meningitis.
    Riordan A
    Curr Opin Neurol; 2010 Jun; 23(3):319-24. PubMed ID: 20173637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of vaccine research and development: meningococcal disease.
    Girard MP; Preziosi MP; Aguado MT; Kieny MP
    Vaccine; 2006 May; 24(22):4692-700. PubMed ID: 16621189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paving the way for the introduction of new vaccines into developing countries.
    Chabalgoity JA
    Expert Rev Vaccines; 2005 Apr; 4(2):147-50. PubMed ID: 15889986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal vaccine in travelers.
    Wilder-Smith A
    Curr Opin Infect Dis; 2007 Oct; 20(5):454-60. PubMed ID: 17762777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries.
    Jódar L; LaForce FM; Ceccarini C; Aguado T; Granoff DM
    Lancet; 2003 May; 361(9372):1902-4. PubMed ID: 12788589
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccines against poverty.
    MacLennan CA; Saul A
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12307-12. PubMed ID: 25136089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.
    Kulkarni PS; Socquet M; Jadhav SS; Kapre SV; LaForce FM; Poonawalla CS
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S483-8. PubMed ID: 26553678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.
    Jadhav S; Datla M; Kreeftenberg H; Hendriks J
    Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives.
    Mueller JE
    Trop Med Int Health; 2013 Jan; 18(1):58-64. PubMed ID: 23121399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing multiple vaccines in low- and lower-middle-income countries: issues, opportunities and challenges.
    Gordon WS; Jones A; Wecker J
    Health Policy Plan; 2012 May; 27 Suppl 2():ii17-26. PubMed ID: 22513729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.